Two-Pronged attack on tough cancers shows promise
NCT ID NCT01116648
Summary
This study tested a combination of two drugs, cediranib and olaparib, for people with recurrent ovarian, fallopian tube, peritoneal, or triple-negative breast cancer. The goal was to see if using both drugs together is safe and works better than using olaparib alone to control the cancer's growth. The trial involved 155 participants and aimed to find the best dose and measure how long patients lived without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard
Fort Wayne, Indiana, 46804, United States
-
Fort Wayne Medical Oncology and Hematology Inc-Parkview
Fort Wayne, Indiana, 46845, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Charlestown, Massachusetts, 02129, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
National Cancer Institute
Rockville, Maryland, 20850, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Newton-Wellesley Hospital
Newton, Massachusetts, 02462, United States
-
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.